专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007041079A2 BANDED CONTROLLED RELEASE NANOPARTICLE ACTIVE AGENT FORMULATION DOSAGE FORMS AND METHODS 审中-公开
标题翻译：带状控制释放纳米粒子活性剂配方剂型及方法
公开(公告)号：WO2007041079A2
公开(公告)日：2007-04-12
申请号：PCT/US2006/037330
申请日：2006-09-25
申请人： ALZA CORPORATION , WONG, Patrick, S.L. , LAM, Andrew, C.
发明人： WONG, Patrick, S.L. , LAM, Andrew, C.
CPC分类号： A61K9/146 , A61K9/1075 , A61K9/145 , A61K9/1611 , A61K9/1652 , A61K9/2072 , A61K9/2077 , A61K9/2095 , B82Y5/00
摘要： Disclosed are controlled release dosage forms and related methods wherein controlled release of self-dispersing nanoparticle active agent formulations is provided by formulating porous particles into which have been sorbed a self-dispersing nanoparticle active agent formulation.
摘要翻译：公开了控释剂型和相关方法，其中通过配制多孔颗粒提供自分散纳米颗粒活性剂制剂的控制释放，其中已经吸收了自分散纳米颗粒活性剂制剂。

2. 发明申请

WO2005030165A1 DOSAGE FORM FOR CONTROLLED RELEASE OF AN ACTIVE AGENT FORMULATION 审中-公开
标题翻译：用于控制释放活性剂配方的剂型
公开(公告)号：WO2005030165A1
公开(公告)日：2005-04-07
申请号：PCT/US2004/031309
申请日：2004-09-23
申请人： ALZA CORPORATION , WISER, Lauren, M. , YU, Betty , CAPELL, Kimberly, R. , LAM, Andrew, C. , HATAMKANY, Zahedeh
发明人： WISER, Lauren, M. , YU, Betty , CAPELL, Kimberly, R. , LAM, Andrew, C. , HATAMKANY, Zahedeh
IPC分类号： A61K9/00
CPC分类号： A61K31/167 , A61K9/0004
摘要： The present invention is directed to a dosage form configured to provide the controlled release of an active agent formulation. A dosage form according to the present invention includes a reservoir containing an active agent formulation and an engine positioned at least partially within the reservoir. In order to reduce the possibility that the engine included in a dosage form of the present invention will separate from the reservoir either during or after fabrication of the dosage form of the present invention, the engine included in a dosage form according to the present invention is bonded to an inside surface of the reservoir. The present invention also includes methods for preparing a controlled release dosage form.
摘要翻译：本发明涉及配制成提供活性剂制剂的受控释放的剂型。根据本发明的剂型包括含有活性剂制剂的储存器和至少部分地位于储存器内的发动机。为了减少包含在本发明的剂型中的发动机在本发明的剂型的制造期间或之后与储存器分离的可能性，包括在根据本发明的剂型中的发动机是结合到储存器的内表面。本发明还包括制备控释剂型的方法。

3. 发明申请

WO2008054508A2 STABLE NANOSIZED AMORPHOUS DRUG 审中-公开
标题翻译：稳定的纳米非晶药物
公开(公告)号：WO2008054508A2
公开(公告)日：2008-05-08
申请号：PCT/US2007/009264
申请日：2007-04-13
申请人： ALZA CORPORATION , WEI, Min , XU, Shuqian , LAM, Andrew, C.
发明人： WEI, Min , XU, Shuqian , LAM, Andrew, C.
CPC分类号： A61K9/146 , A61K9/145 , A61K31/445
摘要： Disclosed is a population of nanoparticles, together with methods of making a population of nanoparticles, wherein one or more of the nanoparticles includes: an amorphous drug core having an effective diameter less than or equal to about 2.0 microns, wherein the amorphous drug core is substantially free of dopant, and wherein the amorphous drug core includes a drug with properties that satisfy the following relationships: a glass transition temperature greater than or equal to about 50 Deg. C, a glass forming ability less than or equal to about 0.85; and water solubility at 25 Deg. C less than or equal to about 1 mg/ml; and at least one stabilizer adsorbed on a surface of the amorphous drug core; and wherein the population of nanoparticles exhibits greater than about six months amorphous stability.
摘要翻译：公开了纳米颗粒群体以及制备纳米颗粒群体的方法，其中一个或多个纳米颗粒包括：具有小于或等于约2.0微米的有效直径的无定形药物核心其中所述无定形药心基本上不含掺杂剂，并且其中所述无定形药心包括具有满足以下关系的性质的药物：玻璃化转变温度大于或等于约50℃。 C，玻璃形成能力小于或等于约0.85; 和在25℃下的水溶性。 C小于或等于约1mg / ml; 和至少一种吸附在无定形药心表面上的稳定剂; 并且其中纳米颗粒群表现出大于约六个月的非晶稳定性。

4. 发明申请

WO2005011630A2 OSMOTIC ENGINE AND DOSAGE FORM FOR CONTROLLED RELEASE OF A LIQUID ACTIVE AGENT FORMULATION 审中-公开
标题翻译：控制释放液体活性剂制剂的渗透发动机和剂型
公开(公告)号：WO2005011630A2
公开(公告)日：2005-02-10
申请号：PCT/US2004/024921
申请日：2004-07-30
申请人： ALZA CORPORATION , YU, Betty , DONG, Liang-Chang , LAM, Andrew, C. , POLLOCK-DOVE, Crystal
发明人： YU, Betty , DONG, Liang-Chang , LAM, Andrew, C. , POLLOCK-DOVE, Crystal
IPC分类号： A61K9/00
CPC分类号： A61K9/0004
摘要： The present invention relates to osmotic engines and dosage forms providing the controlled release of a liquid active agent formulation. More specifically, the present invention is directed to osmotic engines, dosage forms and methods that preserve osmotic engine functionality and reduce void volume formation is osmotically driven dosage form providing the controlled release of liquid active agent formulations.
摘要翻译：本发明涉及提供液体活性剂制剂控释的渗透引擎和剂型。更具体而言，本发明涉及保持渗透引擎功能性并减少空隙体积形成的渗透引擎，剂型和方法，是渗透驱动剂型，提供液体活性剂制剂的受控释放。

5. 发明申请

WO2008002485A3 INCREASED AMORPHOUS STABILITY OF POORLY WATER SOLUBLE DRUGS BY NANOSIZING 审中-公开
公开(公告)号：WO2008002485A3
公开(公告)日：2008-01-03
申请号：PCT/US2007/014585
申请日：2007-06-22
申请人： ALZA CORPORATION , WEI, Min , XU, Shuqian , LAM, Andrew, C.
发明人： WEI, Min , XU, Shuqian , LAM, Andrew, C.
IPC分类号： A61K9/14 , A61K31/00
摘要： Disclosed is a population of nanoparticles, together with methods of making a population of nanoparticles, wherein wherein one or more of the nanoparticles includes: an amorphous drug core having an effective diameter less than or equal to about 2.0 microns, wherein the amorphous drug core is substantially free of dopant, and wherein the amorphous drug core comprises a drug with properties that satisfy the following relationships: a glass transition temperature greater than or equal to about 30 Deg. C; and water solubility at 25 Deg. C less than or equal to about 1 mg/ml; and at least one stabilizer adsorbed on a surface of the amorphous drug core; and wherein the at least one stabilizer is present in an amount effective to provide an amorphous stability of the population of nanoparticles that is approximately equal to or greater than an amorphous stability of an amorphous bulk drug substance comprising the drug, as measured over a period of at least four months.

6. 发明申请

WO2003092649A3 REDUCED FORMATE POLY(ALKYLENE OXIDES) WITH SECONDARY AMINES FOR REDUCING IMPURITY FORMATION 审中-公开
公开(公告)号：WO2003092649A3
公开(公告)日：2003-11-13
申请号：PCT/US2003/013156
申请日：2003-04-28
申请人： ALZA CORPORATION C/O JOHNSON & JOHNSON
发明人： SEROFF, Sylvia, L. , YAM, Noymi, V. , AYER, Atul, D. , LAM, Andrew, C.
IPC分类号： A61K9/00
摘要： Oral delivery vehicles and compositions for providing sustained release of secondary amines including reboxetine with reduced formate poly(alkylene oxide) polymers are provided. Processes for reducing the amount of the formic compounds from the polymers comprising contacting the polymers with an acid having a Pka lower than that of formic acid are also disclosed.

7. 发明申请

WO2003092649A2 REDUCED FORMATE POLY(ALKYLENE OXIDES) WITH SECONDARY AMINES FOR REDUCING IMPURITY FORMATION 审中-公开
标题翻译：减少成型聚亚烷基氧化物（亚烷基氧化物），具有减少造成沉积的二级胺
公开(公告)号：WO2003092649A2
公开(公告)日：2003-11-13
申请号：PCT/US2003/013156
申请日：2003-04-28
申请人： ALZA CORPORATION C/O JOHNSON & JOHNSON
发明人： SEROFF, Sylvia, L. , YAM, Noymi, V. , AYER, Atul, D. , LAM, Andrew, C.
IPC分类号： A61K9/00
CPC分类号： A61K31/5375 , A61K9/0004 , A61K9/2031 , A61K31/765 , A61K47/34
摘要： Oral delivery vehicles and compositions for providing sustained release of secondary amines including reboxetine with reduced formate poly(alkylene oxide) polymers are provided. Processes for reducing the amount of the formic compounds from the polymers comprising contacting the polymers with an acid having a Pka lower than that of formic acid are also disclosed.
摘要翻译：提供口服递送载体和用于提供仲胺持续释放的组合物，其包括与缩合的甲酸酯聚（环氧烷）聚合物的瑞波西汀。还公开了用于从聚合物中降低甲酸化合物的量的方法，包括使聚合物与低于甲酸的Pka的酸接触。

8. 发明公开

EP1933811A2 BANDED CONTROLLED RELEASE NANOPARTICLE ACTIVE AGENT FORMULATION DOSAGE FORMS AND METHODS 审中-公开
标题翻译：相关的纳米颗粒用量的活性控释制剂和方法
公开(公告)号：EP1933811A2
公开(公告)日：2008-06-25
申请号：EP06815377.4
申请日：2006-09-25
申请人： Alza Corporation
发明人： WONG, Patrick, S.L. , LAM, Andrew, C.
IPC分类号： A61K9/00
CPC分类号： A61K9/146 , A61K9/1075 , A61K9/145 , A61K9/1611 , A61K9/1652 , A61K9/2072 , A61K9/2077 , A61K9/2095 , B82Y5/00
摘要： Disclosed are controlled release dosage forms and related methods wherein controlled release of self-dispersing nanoparticle active agent formulations is provided by formulating porous particles into which have been sorbed a self-dispersing nanoparticle active agent formulation.

9. 发明授权

EP1083879B1 DEVICES FOR PROVIDING PROLONGED DRUG THERAPY 有权
标题翻译：在长时间的药物治疗器械到达
公开(公告)号：EP1083879B1
公开(公告)日：2004-09-29
申请号：EP99955212.8
申请日：1999-05-27
申请人： ALZA CORPORATION
发明人： AYER, Atul, D. , CHRISTOPHER, Carol, A. , GUINTA, Diane, R. , GUPTA, Suneel, K. , HAMEL, Lawrence, G. , HATAMKHANY, Zahedeh , LAM, Andrew, C. , SAKS, Samuel, R. , SHIVANAND, Padmaja , WEYERS, Richard, G. , WRIGHT, Jeri, D.
IPC分类号： A61K9/00 , A61K9/22 , A61K31/21
CPC分类号： A61K31/4402 , A61K9/0004 , A61K31/137 , A61K31/421 , A61K31/4422 , A61K31/4458 , G01N21/9508
摘要： Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

10. 发明公开

EP1083879A1 METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY 有权
标题翻译：在长时间的药物治疗器械到达
公开(公告)号：EP1083879A1
公开(公告)日：2001-03-21
申请号：EP99955212.8
申请日：1999-05-27
申请人： ALZA CORPORATION
发明人： AYER, Atul, D. , CHRISTOPHER, Carol, A. , GUINTA, Diane, R. , GUPTA, Suneel, K. , HAMEL, Lawrence, G. , HATAMKHANY, Zahedeh , LAM, Andrew, C. , SAKS, Samuel, R. , SHIVANAND, Padmaja , WEYERS, Richard, G. , WRIGHT, Jeri, D.
IPC分类号： A61K9/00 , A61K9/22 , A61K31/21
CPC分类号： A61K31/4402 , A61K9/0004 , A61K31/137 , A61K31/421 , A61K31/4422 , A61K31/4458 , G01N21/9508
摘要： Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式